Compare GNLX & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | RVLV |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 1.8B |
| IPO Year | 2022 | 2018 |
| Metric | GNLX | RVLV |
|---|---|---|
| Price | $2.63 | $24.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $19.80 | ★ $29.73 |
| AVG Volume (30 Days) | 162.5K | ★ 687.6K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 24.64 |
| EPS | N/A | ★ 0.86 |
| Revenue | $8,000.00 | ★ $1,225,682,000.00 |
| Revenue This Year | N/A | $10.96 |
| Revenue Next Year | N/A | $8.01 |
| P/E Ratio | ★ N/A | $27.05 |
| Revenue Growth | N/A | ★ 8.48 |
| 52 Week Low | $2.21 | $16.80 |
| 52 Week High | $8.54 | $31.68 |
| Indicator | GNLX | RVLV |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 59.25 |
| Support Level | $2.54 | $20.18 |
| Resistance Level | $3.00 | $26.65 |
| Average True Range (ATR) | 0.18 | 0.94 |
| MACD | 0.03 | 0.36 |
| Stochastic Oscillator | 60.91 | 85.16 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.